Program
QLC5513
A development code. Also written as “QLC5513 IV infusion”.
Its studies are led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 11 open or running | phase 2since Nov 26, 2025 | Nov 26, 2025 | Jun 2027phase 2 · NCT07272590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2025First study: phase 2 study in Metastatic Solid TumorsFirst studyNCT07272590 · 290 planned
Ahead
- Jun 2027Primary completion: phase 2 study in Metastatic Solid TumorsNCT07272590
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07272590Metastatic Solid Tumors | 2 | Not yet recruiting | Jun 2027 | 290 |
How it is read
Names in the registry
- “QLC5513 IV infusion”, 1 entry
Codes read as this program: QLC5513.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.